Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Profound Medical's Business Segments

Profound Medical's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Reportable Segments
-
Per the company's own filing, this quarter
Largest Segment
-
Total Revenue
$ 5
Consolidated, this quarter
Countrys Reported
3
Geographic countrys, this quarter
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/PROF/segments
https://api.csimarket.com/api/v1/companies/PROF/geographic
https://api.csimarket.com/api/v1/companies/PROF/exposure
Programmatic access for models, analytics, and integration workflows.
Dataset & schema
https://api.csimarket.com/api/datasets/business_segments
https://api.csimarket.com/api/schema/business_segments
https://api.csimarket.com/api/meta/business_segments

Revenue Share by Country -

67%largest
  • CA66.9%
  • US30.3%
  • DE2.8%

Revenue by Geographic Country -

CountryPeriodRevenue
(Millions)
% of Total
CA$ 466.9%
US$ 230.3%
DE$ 02.8%

Revenue by Product & Service Category -

54%largest
  • Capital equipment53.6%
  • Recurring Non Capital46.4%

Revenue by Product & Service Category -

CategoryPeriodRevenue
(Millions)
% of Total
Capital equipment$ 353.6%
Recurring Non Capital$ 246.4%

Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.

Description of Profound Medical

The company is a commercial-stage medical device firm specializing in AI-powered, MRI-guided, incision-free therapies for tissue ablation using proprietary platform technologies. Its lead product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback to ablate malignant or benign prostate tissue. The TULSA-PRO system is FDA-cleared as a Class II device in the United States for thermal ablation of prostate tissue, CE Marked in the European Union, and approved by Health Canada. The Sonalleve system is CE Marked in the EU for ablation of uterine fibroids, adenomyotic tissue, bone metastases pain relief, osteoid osteoma, and benign desmoid tumors, with additional approvals in China, South Korea, and FDA Humanitarian Device Exemption approval for osteoid osteoma treatment. Both systems are compatible with select MRI scanners from Philips, Siemens, and GE Healthcare. The company generates revenue from sales of capital equipment and recurring one-time-use devices and services. It continues to pursue regulatory approvals and invests in research and development and clinical studies to support coverage and reimbursement. The TULSA-PRO system delivers ultrasound energy via a transurethral catheter with MRI thermometry and robotic control to precisely ablate prostate tissue while preserving surrounding structures. The Sonalleve system delivers focused ultrasound externally to ablate targeted tissue. Clinical studies have demonstrated the safety, precision, and efficacy of these systems for prostate and other tissue ablation.
Profound Medical Corp is a medical technology company primarily focused on developing and commercializing innovative technologies for the treatment of various medical conditions, particularly prostate cancer. The company has developed a unique platform that integrates ultrasound, magnetic resonance imaging (MRI), and thermal ablation to provide precise, targeted therapies.

Segments

1. Prostate Cancer Treatment:
- Profound Medical is best known for its advancements in prostate cancer treatment, particularly through the TULSA-PRO system. This segment focuses on providing solutions for men diagnosed with localized prostate cancer.

2. Thermal Ablation Technologies:
- The company provides thermal ablation services, which utilize heat to destroy cancerous tissue. This technology is often combined with imaging capabilities to enhance precision and effectiveness.

3. Ultrasound and MRI Integration:
- Profound Medical prides itself on combining high-intensity focused ultrasound (HIFU) with MRI technology. This integration allows for real-time visualization during the treatment process, ensuring that clinicians can treat the intended tissue while minimizing damage to surrounding healthy structures.

4. Healthcare Technology Solutions:
- The companys offerings extend to broader healthcare technology solutions that aim to improve procedural workflows and patient outcomes in various medical fields beyond just urology.

Products

1. TULSA-PRO:
- The flagship product of Profound Medical, TULSA-PRO is a device designed for the treatment of prostate cancer. It offers a minimally invasive approach to ablation while utilizing MRI guidance for accurate placement and treatment of the affected area.
- The system allows for the customization of treatment plans, enabling physicians to adjust parameters based on the specific presentation of the patients cancer.

2. TULSA Technology:
- This proprietary technology underpins the TULSA-PRO device, allowing for real-time imaging and precise thermal energy delivery. It enables clinicians to visualize the prostate and surrounding tissues, enhancing the safety and efficacy of the treatment.

3. MediTULSA:
- A service related to TULSA-PRO that offers clinicians a structured platform for performing prostate procedures with enhanced confidence and efficacy. It may include training and support as well as access to treatment protocols.

4. Research and Development Services:
- Profound Medical is involved in ongoing research to enhance its technology and explore applications in other areas of oncology and beyond. This segment is focused on advancing the capabilities of its products and potentially developing new procedures.

Services

1. Clinical Support and Training:
- Profound Medical offers extensive training for healthcare professionals who will use the TULSA-PRO system. This includes both pre- and post-procedure education to ensure that clinicians are proficient in using the technology effectively.

2. Patient Support Programs:
- The company may provide resources and support for patients undergoing treatment with its products. This could include educational materials, guidelines for care post-procedure, and channels for addressing patient concerns.

3. Implementation Support:
- Work with healthcare facilities to facilitate the adoption of TULSA-PRO technology. This may involve helping to integrate the system into clinical workflows, addressing infrastructure needs, and collaborating on best practices for implementation.

4. Post-Procedure Monitoring:
- Follow-up services to monitor patient outcomes, gather data for further research, and ensure that patients are recovering as expected after treatment.

5. Regulatory and Compliance Consultation:
- Given the medical nature of its products, Profound Medical may engage in activities related to ensuring compliance with medical regulations and standards, guiding healthcare providers through the regulatory landscape.

Profound Medical Corp continues to focus on innovation within the medical treatment landscape, particularly within oncology, striving to provide safer and more effective treatment options for patients and healthcare providers alike. The combination of advanced imaging with minimally invasive thermal ablation represents a significant advance in the treatment of prostate cancer and suggests potential expansion into other therapeutic areas in the future.